Cancer Drugs Fund Extended As Pharma Calls For U.K. HTA Rethink
Drug manufacturers say the announced two-year extension for Britain’s Cancer Drugs Fund would not have been needed if NICE was not so focused on cost.
Drug manufacturers say the announced two-year extension for Britain’s Cancer Drugs Fund would not have been needed if NICE was not so focused on cost.